Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent and are willing to take part in the study voluntarily.
• People whose esophageal cancer has been confirmed by laboratory testing of tissue or cell samples as squamous cell carcinoma.
• People whose cancer is located in the chest portion of the esophagus and has been assessed by scans as locally advanced (at a specific stage range), meaning it has not spread to distant parts of the body (confirm with trial site for staging details).
• People whose cancer is considered likely to be fully removed by surgery (no cancer left behind).
• People aged between 18 and 75 years, of any gender.
• People with a good general level of physical functioning, able to carry out daily activities with little or no restriction (rated 0 or 1 on a standard medical scale).
• People who have not had any previous treatment for esophageal cancer, including radiation, chemotherapy, or surgery.
• People who are planning to have surgery after completing the pre-surgery treatment in this trial.
• People who have no medical reasons preventing them from having surgery.
• People whose blood counts, liver function, kidney function, and blood clotting results fall within acceptable ranges (as measured by standard blood tests, without certain blood-boosting medications having been used in the 14 days before starting the trial drug).
• Women who could become pregnant must have a negative pregnancy test within 72 hours before starting the trial drug, and must use effective contraception during the study and for at least 3 months after the last dose. Men with a partner who could become pregnant must be surgically sterilised or agree to use effective contraception during the study and for 3 months after the last dose.
• People who are willing and able to follow the study requirements and attend follow-up appointments.

Who may not be able to join:

• People whose tumour has clearly grown into nearby structures such as major blood vessels or the windpipe.
• People who have cancer spread to the lymph nodes above the collarbone.
• People with fluid build-up around the lungs, heart, or abdomen that cannot be controlled and requires repeated draining.
• People who are significantly underweight (BMI below 18.5), unless this has been addressed with nutritional support before joining and is approved by the lead investigator.
• People with a known allergy to monoclonal antibodies, the study drug Adebrelimab or its components, paclitaxel, cisplatin, or other platinum-based drugs.
• People who have previously received any anti-cancer treatment, including radiation, chemotherapy, or other anti-tumour drugs.
• People who have taken strong immune-suppressing medications or high-dose steroid tablets (above a certain daily dose) within 2 weeks before starting the trial drug (some inhaled or skin-applied steroids may be allowed — confirm with trial site).
• People who have received a live vaccine within 4 weeks before starting the trial drug.
• People who have had major surgery or a serious injury within 4 weeks before starting the trial drug.
• People with active autoimmune diseases (where the immune system attacks the body), or a history of certain autoimmune conditions such as lung inflammation, bowel inflammation, liver inflammation, or thyroid problems (some exceptions may apply — confirm with trial site).
• People with a history of immune system deficiency, a positive HIV test, other immune deficiency conditions, or who have had an organ transplant or bone marrow transplant from a donor.
• People with poorly controlled heart conditions, including significant heart failure, unstable chest pain, a heart attack within the past year, or serious irregular heartbeat that has not been well controlled.
• People who have had a serious infection in the 4 weeks before starting the trial drug, or who have signs of active infection or are currently taking antibiotics (other than for prevention) within 14 days before starting.
• People with active tuberculosis, a history of active tuberculosis in the past year, or a history of tuberculosis more than a year ago that was not properly treated.
• People with active hepatitis B or hepatitis C infections at levels above specified thresholds.
• People diagnosed with another cancer within the past 5 years, unless it was a very low-risk cancer that has been fully treated (such as certain skin cancers or early-stage cervical changes).
• People who are pregnant or breastfeeding.
• People with other serious conditions — including significant mental health conditions, alcohol or drug dependency, or personal or social circumstances — that the investigator considers would make participation unsafe or difficult to complete.

Important: Always verify eligibility with the trial site directly before applying.